Procedural Feasibility and Clinical Outcomes in Propensity-Matched Patients Treated With Bioresorbable Scaffolds vs New-Generation Drug-Eluting Stents

Canadian Journal of Cardiology

Volumn 31, Issue 3, 2015, Pages 328-334

  Sato, Katsumasa ^a   Latib, Azeem ^a   Panoulas, Vasileios F ^a,b   Kawamoto, Hiroyoshi ^a   Naganuma, Toru ^a   Miyazaki, Tadashi ^a   Colombo, Antonio ^a  

^a EMO GVM CENTRO CUORE COLUMBUS   (Italy)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CONTRAST MEDIUM; PRASUGREL; TICAGRELOR; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

AGED; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; BALLOON DILATATION; BIORESORBABLE SCAFFOLD; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG ELUTING CORONARY STENT; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESSURE; PROPENSITY SCORE; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; BIODEGRADABLE IMPLANT; COMPARATIVE STUDY; CORONARY OCCLUSION; DRUG ELUTING STENT; EVALUATION STUDY; KAPLAN MEIER METHOD; MIDDLE AGED; PROCEDURES; PROSTHESIS; REPRODUCIBILITY; TISSUE SCAFFOLD; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY OCCLUSION; DRUG-ELUTING STENTS; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPENSITY SCORE; PROSTHESIS DESIGN; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SIROLIMUS; TISSUE SCAFFOLDS; TREATMENT OUTCOME;

EID: 84923892471     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.12.001     Document Type: Article

References (25)

1. Ormiston J.A., Serruys P.W., Regar E., et al. Abioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008, 371:899-907.
2. Onuma Y., Dudek D., Thuesen L., et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv 2013, 6:999-1009.
3. Serruys P.W., Onuma Y., Garcia-Garcia H.M., et al. Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 2014, 9:1271-1284.
4. Thygesen K., Alpert J.S., Jaffe A.S., et al. Third universal definition of myocardial infarction. JAm Coll Cardiol 2012, 60:1581-1598.
5. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007, 115:2344-2351.
6. Austin P.C., Mamdani M.M. Acomparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med 2006, 25:2084-2106.
7. Miyazaki T., Panoulas V.F., Sato K., Naganuma T., Latib A., Colombo A. Acute stent thrombosis of a bioresorbable vascular scaffold implanted for ST-segment elevation myocardial infarction. Int J Cardiol 2014, 174:e72-e74.
8. Serruys P.W., Onuma Y., Ormiston J.A., et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 2010, 122:2301-2312.
9. Serruys P.W., Chevalier B., Dudek D., et al. Abioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2015, 385:43-54.
10. Capodanno D, Gori T, Nef H, etal. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2015;10:1144-53.
11. Kraak RP, Hassell ME, Grundeken MJ, etal. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry. EuroIntervention 2015;10:1160-8.
12. Lotan C., Meredith I.T., Mauri L., Liu M., Rothman M.T. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry. JACC Cardiovasc Interv 2009, 2:1227-1235. Investigators EF.
13. Krucoff M.W., Rutledge D.R., Gruberg L., et al. Anew era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study). JACC Cardiovasc Interv 2011, 4:1298-1309.
14. Cadrin-Tourigny J., Dong L., Maehara A., Schampaert E., Genereux P. Bioresorbable vascular scaffold use in a case of in-stent restenosis. Arq Bras Cardiol 2014, 103:e11-e14.
15. Mattesini A., Secco G.G., Dall'Ara G., et al. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance. JACC Cardiovasc Interv 2014, 7:741-750.
16. Gomez-Lara J., Garcia-Garcia H.M., Onuma Y., et al. Acomparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc Interv 2010, 3:1190-1198.
17. Ielasi A., Latib A., Naganuma T., et al. Early results following everolimus-eluting bioresorbable vascular scaffold implantation for the treatment of in-stent restenosis. Int J Cardiol 2014, 173:513-514.
18. Panoulas V.F., Miyazaki T., Sato K., et al. Hybrid percutaneous coronary revascularisation for a patient with left main bifurcation and extensive, diffuse coronary artery disease. Int J Cardiol 2014, 173:e20-e22.
19. Sato K., Latib A., Panoulas V.F., et al. Acase of true left main bifurcation treated with bioresorbable everolimus-eluting stent v-stenting. JACC Cardiovasc Interv 2014, 7:e103-e104.
20. Naganuma T., Basavarajaiah S., Latib A., Costopoulos C., Colombo A. Use of BVS in a chronic total occlusion with bifurcation lesion. Int J Cardiol 2013, 167:e129-e131.
21. Naganuma T., Costopoulos C., Latib A., et al. Feasibility and efficacy of bioresorbable vascular scaffolds use for the treatment of in-stent restenosis and a bifurcation lesion in a heavily calcified diffusely diseased vessel. JACC Cardiovasc Interv 2014, 7:e45-e46.
22. Frey A.W., Hodgson J.M., Muller C., Bestehorn H.P., Roskamm H. Ultrasound-Guided Strategy for Provisional Stenting With Focal Balloon Combination Catheter: Results from the Randomized Strategy for Intracoronary Ultrasound-Guided PTCA and Stenting (SIPS) trial. Circulation 2000, 102:2497-2502.
23. Kim J.S., Kang T.S., Mintz G.S., et al. Randomized comparison of clinical outcomes between intravascular ultrasound and angiography-guided drug-eluting stent implantation for long coronary artery stenoses. JACC Cardiovasc Interv 2013, 6:369-376.
24. Oemrawsingh P.V. Intravascular ultrasound guidance improves angiographic and clinical outcome of stent implantation for long coronary artery stenoses: final results of a randomized comparison with angiographic guidance (TULIP study). Circulation 2002, 107:62-67.
25. Witzenbichler B., Maehara A., Weisz G., et al. Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study. Circulation 2014, 129:463-470.